Drug Profile
Dimethyl fumarate - Almirall
Alternative Names: LAS-41008; SkilarenceLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Almirall S.A.
- Class Anti-inflammatories; Antihypertensives; Antipsoriatics; Antirheumatics; Cardiovascular therapies; Cytoprotectives; Esters; Fumarates; Small molecules
- Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Psoriasis
Highest Development Phases
- Marketed Plaque psoriasis
Most Recent Events
- 07 Sep 2021 Almirall completes the phase III DIMESKIN 2 trial in Plaque psoriasis in Italy (PO) (EudraCT2017-003818-11)
- 01 Aug 2018 Almirall plans to market dimethyl fumarate in European Union, Iceland, Norway and Switzerland
- 12 Mar 2018 Phase III clinical trial in Plaque psoriasis in Italy (PO) (EudraCT2017-003818-11)